NCT01588145已完成1 期
Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HM61713 in NSCLC Patients With EGFR Mutation
Hanmi Pharmaceutical Company Limited0 个研究点目标入组 273 人开始时间: 2012年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 273
- 主要终点
- Safety and tolerability
研究概览
简要总结
The main objective of this study is to evaluate the safety and tolerability of HM61713.
详细描述
Besides the main objective, there are 3 other objectives as follows:
- To evaluate the anti-cancer effect of HM61713 in NSCLC patients with EGFR mutation
- To investigate the pharmacokinetic profile of HM61713 and its metabolites after oral administration
- To investigate biomarkers related to the safety and efficacy of HM61713
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histologically or cytologically confirmed diagnosis of advanced NSCLC
- •Patients with EGFR mutation-positive tumor
- •Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
- •Estimated life expectancy of at least 12 weeks
- •Subjects with adequate bone marrow (WBC ≥4,000/mm3, Platelet ≥100,000/mm3, Hemoglobin≥9.0g/dL, ANC≥1,500/mm3), renal (Creatinine≤1.5 mg/dl) and hepatic [aspartate aminotransferase (AST)/ alanine aminotransferase (ALT)/ alkaline phosphatase (ALP)≤3 x ULN, Total bilirubin ≤2.0 mg/dL] function. No significant heart and lung disease.
- •※ For subjects with a liver metastases, AST/ALT/ALP≤ 5 x ULN is allowed; and for subjects with bone marrow metastases, ALP≤ 5 x ULN is allowed
- •Patients with amylase level ≤ 1.5 x ULN
- •Subjects who have provided voluntary consent to participate in the study, and signed the written consent document
- •<Dose escalation part>
- •Malignancy that has progressed after at least two prior chemotherapy regimens, including EGFR-TKI
- •<Expansion part 1>
- •Patients with disease progression despite anticancer therapy with EGFR-TKI (e.g., erlotinib, gefitinib, neratinib, afatinib, dacomitinib)
- •Patients who have provided voluntary consent for collection of tumor tissue taken and archived after the last anticancer therapy or collection of new tissue specimen and signed the written consent document
- •<Expansion part 2> & <Phase 2>
- •Patients with disease progression despite anticancer therapy with EGFR TKI (e.g., erlotinib, gefitinib, neratinib, afatinib, dacomitinib) (Except treatment with EGFR mutation selective inhibitor, the same class of drug as investigational drug in this study)
- •T790M mutation-positive confirmed in tissue collected after PD is confirmed during or after the last anticancer therapy
- •At least one measurable target lesion allowing repeated measurement according to RECIST ver1.1 as of screening
- •<Phase 1 Expansion part 3>
- •Patients with disease progression despite anticancer therapy with EGFR TKI (e.g., erlotinib, gefitinib, neratinib, afatinib, dacomitinib) (Except treatment with EGFR mutation selective inhibitor, the same class of drug as investigational drug in this study)
- •T790M mutation-negative confirmed in tissue collected after progressive disease (PD) is confirmed during or after the last anticancer therapy
- •At least one measurable target lesion allowing repeated measurement according to RECIST ver1.1 as of screening
排除标准
- •Hematologic malignancies
- •Symptomatic or uncontrolled central nervous system metastases
- •Interstitial lung disease, including pulmonary fibrosis
- •LVEF < 40% or NYHA Class III or IV heart failure
- •History of pancreatitis
- •History or current evidence, of any psychiatric or congenital disorder, including dementia or epilepsy
- •Compromised organ function, infection or allergy
- •Pregnant or breast-feeding women, or women of child-bearing potential who do not use an appropriate method of contraception (male patients should also use an appropriate method of contraception during the study period)
- •Patients who had received other investigational product within 30 days prior to screening
研究组 & 干预措施
HM61713
Experimental
干预措施: HM61713 (Drug)
结局指标
主要结局
Safety and tolerability
时间窗: Dose limiting Toxicity will be evaluated on Day 24 during Cycle 1
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid TumorsNCT04047862BeiGene446
已完成
1 期
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast CancerSolid Tumors and LymphomasNCT02392611Gilead Sciences33
已完成
1 期
A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric CancerHER-2 Positive Advanced Gastric CancerNCT01746771Hanmi Pharmaceutical Company Limited44
已完成
1 期
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid TumorsMTAP-null Non-Small-Cell Lung CancerMTAP-null Solid TumorsNCT05975073Amgen53
招募中
1 期
A Study of CS23546 in Subjects With Advanced TumorsAdvanced TumorsNCT06245122Chipscreen Biosciences, Ltd.156